Drug Profile
PA 300
Alternative Names: PA-300Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Pathologica
- Class
- Mechanism of Action Adenosylmethionine decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Musculoskeletal pain
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Multiple sclerosis in USA (PO)
- 04 Sep 2023 Discontinued - Preclinical for Musculoskeletal pain in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO)